SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) today announced that pre-clinical studies have documented that the Aethlon Hemopurifier® is effective in capturing circulating West Nile Virus (WNV). The study data further supports the potential use of the Hemopurifier® as a broad-spectrum treatment against viral pathogens, whether naturally occurring, or purposely released as biological weapons of mass destruction. During in vitro studies, high concentrations of WNV (approximately 700 thousand WNV/ml) were depleted from cell culture fluids when circulated through the Hemopurifier®. The study data indicated that the Hemopurifier® removed 53 percent of infectious WNV in the first four hours of the testing; 79 percent at six hours; and 99.3 percent after 20 hours. The studies were conducted in triplicate, and data verification was provided by real-time polymerase chain reaction (PCR).
